Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, provides medicines for an array of health concerns in several therapeutic areas. Their 14 acre Cork facility, located in Little Island since 1981, employs over 230 people involved in the manufacture of Active Pharmaceutical Ingredients (API) for human use. Products are distributed across the globe to other Janssen sites and 3rd party companies, where they are further processed into tablets, creams or injectable dosage forms. These finished products are used in the treatment of a range of psychiatric, gastrointestinal and fungal disorders as well as in the treatment of HIV.
CAPPA completed a direct funded Technical Feasibility Study for Janssen in 2010. The study investigated optical solutions to a key process measurement requirement identified in the Cork plant. CAPPA’s expertise in photonic and optical technologies complimented the organisations internal knowledge in other metrology areas. This allowed Janssen to effectively evaluate all potential solutions for their requirements with an equal depth of technical knowledge. Ultimately a non-optical solution was chosen once all options were compared.
“Janssen engaged CAPPA to investigate the suitability of a photonics solution to a pharmaceutical process problem and to compare the merits of this with other possible non-photonics alternatives. We were impressed by their creativity, thoroughness and speed of response.”
Dr. Michael Napier, Director Chemical Technology